Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 4/8/13 → 4/8/19 |
Funding
- ICON Clinical Research, LLC (Prot #CA180399 // Prot #CA180399)
- Bristol-Myers Squibb Company (Prot #CA180399 // Prot #CA180399)
Prot #CA180399: An Open Label, Randomized (2:1) Phase 2b Study of Dasatinib vs. Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy with 400 mg Imatinib
- Frankfurt, Olga (PD/PI)
Project: Research project